{"public_id":"cl_4a25287c3d2435bcec9eccb3c7c442b6","status":"active","superseded_by_public_id":null,"corpus_id":27103283,"text":"Cost-effectiveness declines substantially when treatment efficacy for cancer prevention is low, exceeding $75,000 per year of life saved at efficacy below 10%.","confidence":0.95,"paper":{"corpus_id":27103283,"title":"Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials.","url":"https://sah.borca.ai/papers/27103283"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_6ea2742e22a2dbd2c66f640d305e61d1","name":"gastric cancer prevention","description":"Strategies intended to reduce the occurrence of gastric adenocarcinoma.","types":["clinical outcome","prevention strategy"],"url":"https://sah.borca.ai/concepts/co_6ea2742e22a2dbd2c66f640d305e61d1"},{"public_id":"co_9c19303b82e6a64d082b163212a31059","name":"cost-effectiveness","description":"The ratio of costs to health benefit, expressed here as cost per year of life saved.","types":["outcome measure","economic metric"],"url":"https://sah.borca.ai/concepts/co_9c19303b82e6a64d082b163212a31059"},{"public_id":"co_fddf17d4ba244f41da284d1a89c2d3fb","name":"treatment efficacy","description":"The assumed proportion of attributable gastric cancers prevented by Helicobacter pylori therapy.","types":["model parameter","effectiveness parameter"],"url":"https://sah.borca.ai/concepts/co_fddf17d4ba244f41da284d1a89c2d3fb"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_4a25287c3d2435bcec9eccb3c7c442b6"}